Regulatory aspects for Biologic product licensing in India

  • Sanjeev Kumar Maurya Amity University, India
  • Vikesh Shukla
  • Prachi Kaushik
  • SP Yamini Kanti
  • Anshul Bansal
DOI https://doi.org/10.22270/ijdra.v7i1.287

Abstract

Biologics are the medicinal/ therapeutic/ diagnostic/ preventive preparations composed or derived from living organisms and their spin-off for human use. They include serums, vaccines, antitoxins, blood, antigens and blood components, gene therapy, tissues etc. Biotechnology is used as a unique approach in manufacturing such medicinal agents. The Indian National regulatory authority (CDSCO) is the body that is responsible for manufacturing and import of biological products in India. Biotechnology provides innovative solutions to medical field with more than 200 biologic medicines and vaccines. These developments benefits millions of patients worldwide and more than 600 products under development. At present these products can also be produced by manufacturers other than the innovator, with the expiry of some of patents. These new biotechnological medicines commonly referred to as ‘similar biologics’ offer a major opportunity to provide greater access to reasonable healthcare for several lifesaving medicines. India has emerged as one of the leading providers to the world market for ‘Biosimilars’. These may be considered to be very essential economical and therapeutical element for the pharmaceutical market in India. The Indian National Regulatory Authority is considered to be responsible for evaluating safety, efficacy and quality of all pharmaceuticals in India. The Department of Biotechnology in India is the department that governs the development, pre-clinical studies of all Biologicals.

Keywords: Biologicals, CDSCO, RCGM, DBT, DCGI

Downloads

Download data is not yet available.

References

1. Singh. S, Bisht. A. Regulation of Biological: Indian Perspective. International J Res foundation Hosp Healthc adm. 2015; 3(2) 135-136.
2. Langer. E. Biologics regulation in India: India is restructuring its regulations of biopharmaceuticals. BioPharma International. 2008; 26-29.
3. Regulation of Biologics in India [Internet]. Morula; 2018 [cited 2018 Dec 23]. Available from:
http://morulaa.com/cdsco/regulations-of-biologics-in-india-2/
4. CDSCO guidance for Industry [Internet]. CDSCO; 2008 [cited 2018 Dec 23]. Available from:
http://www.cdsco.nic.in/writereaddata/CDSCO-
5. Rathore A. Guidelines on similar biologics: regulatory requirements for marketing authorization in India. PDAJ Pharm Sci Technol. 2011; 66:393-3.
Statistics
1028 Views | 2142 Downloads
How to Cite
Maurya, S. K., V. Shukla, P. Kaushik, S. Y. Kanti, and A. Bansal. “Regulatory Aspects for Biologic Product Licensing in India”. International Journal of Drug Regulatory Affairs, Vol. 7, no. 1, Mar. 2019, pp. 1-5, doi:10.22270/ijdra.v7i1.287.
Issue
Vol 7 No 1 (2019): VOLUME 7, ISSUE 1, 2019
Section
Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.

I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.

Download link for COPYRIGHT FORM